In 2025, Novo Nordisks semaglutide awaits several first-time FDA decisions: 3Q 2025 the first GLP-1 (Wegovy) for metabolic dysfunction-associated steatohepatitis (MASH) 4Q 2025 the first oral GLP-1 ( oral formulation of Wegovy 25 mg ) for weight loss and weight loss plus secondary CV risk reduction 4Q 2025 Wegovy for heart failure with preserved ejection fraction and obesity October 2025 new indication for oral Rybelsus for secondary CV risk reduction 2025 Ozempic for T2DM and peripheral artery disease (PAD) Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics (Prime) talented team of clinical experts actively monitors this emerging landscape
Reduce Oxidative Load : Avoid excessive processed foods, pollution, and stress, which deplete endogenous antioxidants
Focus on high-quality protein and consider targeted support
As a powerful antioxidant, glutathione not only enhances skin radiance but also boosts immunity and detoxification offering beauty and wellness benefits in one
Your GP can facilitate communication between specialists and may refer you for specialist review if there are concerns about drug interactions or disease management
I push the needle into my thigh for its full length, slowly and firmly
